<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732910</url>
  </required_header>
  <id_info>
    <org_study_id>20012746</org_study_id>
    <nct_id>NCT04732910</nct_id>
  </id_info>
  <brief_title>Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators</brief_title>
  <acronym>Modulate-CF</acronym>
  <official_title>CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study evaluates the effect of therapy with cystic fibrosis transmembrane&#xD;
      regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal&#xD;
      current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a&#xD;
      post-approval setting in patients with cystic fibrosis (CF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis transmembrane regulator (CFTR) biomarker (intestinal current measurement&#xD;
      (ICM), nasal potential difference (NPD), sweat chloride) before the start of therapy and 12&#xD;
      and 52 weeks after initiation of therapy Clinical parameters (anthropometry, lung function,&#xD;
      lung magnetic resonance imaging (MRI), lung computer tomography (CT)) before the start of&#xD;
      therapy and after initiation of therapy Assessment of airway secretion specimens before the&#xD;
      start of therapy and after initiation of therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal current measurement (ICM)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute change from baseline of the chloride secretory ion current induced by cyclic adenosine monophosphate (cAMP) stimulation (forskolin/3-isobutyl-1-methylxanthine (IBMX)) in rectal tissue determined by intestinal current measurement (ICM) as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline in percent predicted forced expiratory volume in 1 second (FEV1) in spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal potential Difference (NPD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute change from baseline total chloride response (zero chloride and isoproterenol) in nasal potential Difference (NPD) as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sweat chloride</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline of the chloride concentration in Gibson-Cooke pilocarpine iontophoresis sweat test as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung clearance index (LCI)</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline of the lung clearance index (LCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung magnetic resonance imaging (MRI)</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline in lung magnetic resonance imaging (MRI) score (Heidelberg MRI score ranging from 0 to 72 with higher values associated with worsening of the outcome; Eichinger et al. Eur J Radiol 2012)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung computer tomography</measure>
    <time_frame>52, 104 weeks</time_frame>
    <description>Absolute change from baseline in lung computer tomography (CT) score (Brody score ranging from 0 to 40,5 with higher values associated with worsening of the outcome; Brody et al. J Thorac Imaging 2006)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paranasal sinus magnetic resonance imaging (MRI)</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline in paranasal sinus magnetic resonance imaging (MRI) score (Sinunasal MRI score ranging from 0 to 68 with higher values associated with worsening of the outcome; Sommerburg et al. Ann Am Thorac Soc 2020)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal elastase</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline in fecal elastase-1 (FE-1) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>12, 52, 104 weeks</time_frame>
    <description>Absolute change from baseline in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Microbiome</measure>
    <time_frame>4, 12, 52, 104 weeks</time_frame>
    <description>Absolute change in shannon index representing the alpha-diversity in sputum samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Elasticity</measure>
    <time_frame>4, 12, 52, 104 weeks</time_frame>
    <description>Absolute change in the elastic modulus (G') in sputum samples measured with a rheometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Viscocity</measure>
    <time_frame>4, 12, 52, 104 weeks</time_frame>
    <description>Absolute change in the viscous modulus (G'') in sputum samples measured with a rheometer</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor</intervention_name>
    <description>observational</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum, Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic Fibrosis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Decision for cystic fibrosis (CF) transmembrane regulator (CFTR)-modulator therapy by&#xD;
             the patient and the caring CF physician&#xD;
&#xD;
          -  Signed informed consent form (ICF) and, where appropriate, signed assent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing participation in an investigational drug study (including studies&#xD;
             investigating lumacaftor, tezacaftor or ivacaftor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Y Graeber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Y Graeber, MD</last_name>
    <phone>+4930 450 566 587</phone>
    <email>simon.graeber@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Graeber, MD</last_name>
      <phone>+4930 450 566 587</phone>
      <email>simon.graeber@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-University Giessen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Nährlich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Tümmler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Sommerburg, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Simon Graeber</investigator_full_name>
    <investigator_title>BIH Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>CFTR</keyword>
  <keyword>ICM</keyword>
  <keyword>NPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
    <mesh_term>Elexacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

